SCHEMBL5439784

SCHEMBL5439784

O=c1ccc(-c2ccc(O)cc2)cn1Cc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
VEGFA P15692 1/20 0.45
EGLN1 Q9GZT9 1/20 0.45
SDHB P21912 1/20 0.45
MKNK1 Q9BUB5 4/20 0.43
MKNK2 Q9HBH9 4/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5195278 0.88 FABP6 (0.47) FABP6ALDH1A1SMN1; SMN2VEGFAEGLN1
SCHEMBL8784736 0.87 MAPT (0.51) FABP6ALDH1A1SMN1; SMN2VEGFAEGLN1
SCHEMBL5439773 0.86 CREBBP (0.53) ALDH1A1SMN1; SMN2SDHBMKNK1MKNK2
SCHEMBL5433212 0.86 ALDH1A1 (0.53) FABP6ALDH1A1SMN1; SMN2SDHBMKNK1
SCHEMBL5183135 0.84 SDHB (0.45) FABP6ALDH1A1SMN1; SMN2SDHBMKNK1
SCHEMBL5437025 0.84 MAPT (0.59) FABP6ALDH1A1SMN1; SMN2SDHBMKNK1
SCHEMBL5439647 0.84 MAPT (0.49) FABP6ALDH1A1SMN1; SMN2SDHBMKNK1
SCHEMBL5443007 0.84 MKNK1 (0.48) FABP6ALDH1A1SMN1; SMN2VEGFAEGLN1
SCHEMBL5438403 0.84 MKNK1 (0.54) ALDH1A1SMN1; SMN2SDHBMKNK1MKNK2
SCHEMBL5448763 0.84 SDHB (0.45) FABP6ALDH1A1SMN1; SMN2SDHBMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US claimed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 FABP6 4112/4885ALDH1A1 3403/4885SMN1; SMN2 1523/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 FABP6 2682/4885ALDH1A1 2717/4885SMN1; SMN2 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.